Cerevel Therapeutics Holdings Inc (CERE)
Cerevel Therapeutics Holdings is a clinical-stage biopharmaceutical company. Co.'s programs: Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype; Darigabat, which is a PAM that selectively targets the alpha-2/3/5 subunits of the GABAA receptor; Tavapadon, which is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of early- and late-stage Parkinson's disease; and CVL-871, which is a selective dopamine D1/D5 receptor partial agonist specifically designed to achieve a level of partial agonism.
CERE SEC Filing Email Alerts Service
Company Name: |
Cerevel Therapeutics Holdings Inc |
Website: |
www.cerevel.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding CERE: |
24 |
Total Market Value Held by ETFs: |
$496.10M |
Total Market Capitalization: |
$7.69B |
% of Market Cap. Held by ETFs: |
6.45% |
|
|
March 29, 2024 4:14 AM Eastern
Hold (2.36 out of 4)
0th percentile
|
|